GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Matinas BioPharma Holdings Inc (AMEX:MTNB) » Definitions » Shiller PE Ratio

Matinas BioPharma Holdings (Matinas BioPharma Holdings) Shiller PE Ratio : (As of May. 22, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Matinas BioPharma Holdings Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Matinas BioPharma Holdings Shiller PE Ratio Historical Data

The historical data trend for Matinas BioPharma Holdings's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Matinas BioPharma Holdings Shiller PE Ratio Chart

Matinas BioPharma Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Matinas BioPharma Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Matinas BioPharma Holdings's Shiller PE Ratio

For the Biotechnology subindustry, Matinas BioPharma Holdings's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Matinas BioPharma Holdings's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Matinas BioPharma Holdings's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Matinas BioPharma Holdings's Shiller PE Ratio falls into.



Matinas BioPharma Holdings Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Matinas BioPharma Holdings's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Matinas BioPharma Holdings's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.03/131.7762*131.7762
=-0.030

Current CPI (Mar. 2024) = 131.7762.

Matinas BioPharma Holdings Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.076 100.560 -0.100
201409 -0.081 100.428 -0.106
201412 -0.100 99.070 -0.133
201503 -0.070 99.621 -0.093
201506 -0.040 100.684 -0.052
201509 -0.040 100.392 -0.053
201512 -0.040 99.792 -0.053
201603 -0.040 100.470 -0.052
201606 -0.030 101.688 -0.039
201609 -0.110 101.861 -0.142
201612 -0.030 101.863 -0.039
201703 -0.250 102.862 -0.320
201706 -0.040 103.349 -0.051
201709 -0.040 104.136 -0.051
201712 -0.040 104.011 -0.051
201803 -0.050 105.290 -0.063
201806 -0.040 106.317 -0.050
201809 -0.030 106.507 -0.037
201812 -0.030 105.998 -0.037
201903 -0.040 107.251 -0.049
201906 -0.030 108.070 -0.037
201909 -0.030 108.329 -0.036
201912 -0.040 108.420 -0.049
202003 -0.030 108.902 -0.036
202006 -0.030 108.767 -0.036
202009 -0.030 109.815 -0.036
202012 -0.030 109.897 -0.036
202103 -0.030 111.754 -0.035
202106 -0.020 114.631 -0.023
202109 -0.030 115.734 -0.034
202112 -0.030 117.630 -0.034
202203 -0.030 121.301 -0.033
202206 -0.030 125.017 -0.032
202209 -0.030 125.227 -0.032
202212 -0.020 125.222 -0.021
202303 -0.030 127.348 -0.031
202306 -0.030 128.729 -0.031
202309 -0.030 129.860 -0.030
202312 -0.030 129.419 -0.031
202403 -0.030 131.776 -0.030

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Matinas BioPharma Holdings  (AMEX:MTNB) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Matinas BioPharma Holdings Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Matinas BioPharma Holdings's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Matinas BioPharma Holdings (Matinas BioPharma Holdings) Business Description

Traded in Other Exchanges
Address
1545 Route 206 South, Suite 302, Bedminster, NJ, USA, 07921
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of product candidates derived from its lipid-crystal nano-particle, or cochleate, delivery technology platform. The firm's pipeline includes MAT2203, MAT2501 and others.
Executives
Liu Hui officer: Chief Technology Officer C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921
Thomas Hoover officer: Chief Business Officer C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921
Kathryn Penkus Corzo director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921
Natasha Giordano director 8285 EL RIO STREET, SUITE 130, HOUSTON TX 77054
Adam K Stern director STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Patrick G Lepore director 17-17 ROUTE 208 N, FAIRLAWN NJ 07410
Jerome D Jabbour director, officer: Chief Executive Officer C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206, SUITE 302, BEDMINSTER NJ 07921
Keith A Kucinski officer: Chief Financial Officer C/O MATINAS BIOPHARMA HOLDINGS INC., 1545 RT. 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Eric J Ende director C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Herbert J Conrad director C/O ARBUTUS BIOPHARMA CORP., 100-8900 GLENLYON PARKWAY, BURNABY A1 V5J 5J8
Ferguson James J. Iii officer: Chief Medical Officer C/O MATINAS BIOPHARMA HOLDINGS INC., 1545 RT. 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Theresa Matkovits officer: Chief Development Officer C/O ARADIGM CORPORATION, 3929 POINT EDEN WAY, HAYWARD CA 94545
Gary Gaglione officer: Chief Financial Officer C/O MATINAS BIOPHARMA HOLDINGS, 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921
Matthew Wikler director VIROPHARMA INCORP, 405 EAGLEVIEW BLVD, EXTON PA 19341
Raphael J Mannino officer: Chief Scientific Officer C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921